ati-50002
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Dec 14, 2017 (NCT03315689)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase JAK3INHIBITOR
JAK3 inhibitor
- Tyrosine-protein kinase JAK1INHIBITOR
JAK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03551821 | Phase 2 | Apr 11, 2018 | Aclaris Therapeutics, Inc. |
| NCT03495817 | Phase 2 | Mar 22, 2018 | Aclaris Therapeutics, Inc. |
| NCT03468855 | Phase 2 | Mar 19, 2018 | Aclaris Therapeutics, Inc. |
| NCT03315689 | Phase 2 | Dec 14, 2017 | Aclaris Therapeutics, Inc. |
| NCT03354637 | Phase 2 | Dec 14, 2017 | Aclaris Therapeutics, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. | For profit | 5 | 5 | 1 | 2017 |
1 organizations
Page 1 / 1